Harvard Bioscience Announces Board and Executive Changes
Ticker: HBIO · Form: 8-K · Filed: Aug 13, 2025 · CIK: 1123494
| Field | Detail |
|---|---|
| Company | Harvard Bioscience Inc (HBIO) |
| Form Type | 8-K |
| Filed Date | Aug 13, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01, $100,000, $50,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation
TL;DR
Harvard Bioscience shakes up board and exec pay. Big changes coming?
AI Summary
Harvard Bioscience, Inc. announced on August 12, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key executives. Specific details regarding the individuals involved and the financial implications of these changes are outlined within the report.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategy, governance, or financial outlook, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate underlying issues or strategic shifts that may affect the company's future performance and stability.
Key Players & Entities
- HARVARD BIOSCIENCE, INC. (company) — Registrant
- August 12, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 84 October Hill Road (address) — Principal Executive Offices
- Holliston, MA 01746 (address) — Principal Executive Offices
- (508) 893-8999 (phone_number) — Registrant's phone number
FAQ
What specific roles have been affected by the departure of directors or certain officers?
The filing indicates departures of directors and certain officers, with specific roles detailed within the report's sections on Item 5.02.
Who are the newly elected directors?
The election of new directors is reported under Item 5.02, with their names and relevant biographical information provided in the filing.
What are the key changes in compensatory arrangements for certain officers?
Item 5.02 of the filing details updates to the compensatory arrangements for specific named officers, including any new agreements or modifications.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this filing occurred on August 12, 2025.
What is Harvard Bioscience, Inc.'s principal executive office address?
Harvard Bioscience, Inc.'s principal executive office is located at 84 October Hill Road, Holliston, MA 01746.
Filing Stats: 645 words · 3 min read · ~2 pages · Grade level 11.1 · Accepted 2025-08-13 16:30:56
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value HBIO The NASDAQ Stock Mar
- $100,000 — be eligible to receive a cash bonus of $100,000 (the "Retention Bonus") upon successful
- $50,000 — Mr. Frost in lieu of the cash bonus of $50,000 provided in Mr. Frost's offer letter fr
Filing Documents
- f8k_081225.htm (8-K) — 23KB
- exh_101.htm (EX-10.1) — 11KB
- 0001171843-25-005377.txt ( ) — 198KB
- hbio-20250812.xsd (EX-101.SCH) — 3KB
- hbio-20250812_lab.xml (EX-101.LAB) — 33KB
- hbio-20250812_pre.xml (EX-101.PRE) — 22KB
- f8k_081225_htm.xml (XML) — 3KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 12, 2025, Harvard Bioscience, Inc. (the "Company") entered into a retention letter agreement (the "Retention Letter Agreement") with Mark Frost, the Company's Interim Chief Financial Officer. The Retention Letter Agreement provides that Mr. Frost will be eligible to receive a cash bonus of $100,000 (the "Retention Bonus") upon successful refinancing of the indebtedness due under the Company's existing term loan and senior revolving credit facility (the "Refinancing") prior to March 15, 2026 (the "Retention Date"). Mr. Frost's eligibility to receive the Retention Bonus is subject to Mr. Frost's continued employment with the Company through the date of the Refinancing and, unless earlier terminated by the Company without cause, the Retention Date. The Retention Bonus is being offered to Mr. Frost in lieu of the cash bonus of $50,000 provided in Mr. Frost's offer letter from the Company dated April 10, 2025. The Retention Letter Agreement also requires the Company to provide certain payments and benefits in the event of termination of Mr. Frost's employment without cause prior to the Retention Date. Such benefits include payment of Mr. Frost's base salary and payment of the Company's portion of COBRA premiums, in each case, for a period of five months from the date of termination, subject to Mr. Frost signing a general release of claims. The foregoing description of the Retention Letter Agreement is qualified in its entirety by reference to the complete text of the Retention Letter Agreement, which is attached hereto as Exhibit 10.1 and incorporated by reference herein.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Retention Letter Agreement between Mark Frost and the Company dated August 12, 2025 104 Cover Page Interactive Data File (embedded within the inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities ExchangeAct of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HARVARD BIOSCIENCE, INC. Date: August 13, 2025 /s/ Mark Frost Mark Frost Interim Chief Financial Officer and Treasurer